Targeting cellular senescence in kidney diseases and aging: A focus on mesenchymal stem cells and their paracrine factors.

Autor: Hejazian SM; Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Hejazian SS; Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.; Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Mostafavi SM; Ayatollah Taleghani Hospital, Research Development Unit, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Hosseiniyan SM; Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Montazersaheb S; Molecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Ardalan M; Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Zununi Vahed S; Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. sepide.zununi@gmail.com., Barzegari A; Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. barzegari.abolfazl@gmail.com.
Jazyk: angličtina
Zdroj: Cell communication and signaling : CCS [Cell Commun Signal] 2024 Dec 18; Vol. 22 (1), pp. 609. Date of Electronic Publication: 2024 Dec 18.
DOI: 10.1186/s12964-024-01968-1
Abstrakt: Cellular senescence is a phenomenon distinguished by the halting of cellular division, typically triggered by DNA injury or numerous stress-inducing factors. Cellular senescence is implicated in various pathological and physiological processes and is a hallmark of aging. The presence of accumulated senescent cells, whether transiently (acute senescence) or persistently (chronic senescence) plays a dual role in various conditions such as natural kidney aging and different kidney disorders. Elevations in senescent cells and senescence-associated secretory phenotype (SASP) levels correlate with decreased kidney function, kidney ailments, and age-related conditions. Strategies involving senotherapeutic agents like senolytics, senomorphics, and senoinflammation have been devised to specifically target senescent cells. Mesenchymal stem cells (MSCs) and their secreted factors may also offer alternative approaches for anti-senescence interventions. The MSC-derived secretome compromises significant therapeutic benefits in kidney diseases by facilitating tissue repair via anti-inflammatory, anti-fibrosis, anti-apoptotic, and pro-angiogenesis effects, thereby improving kidney function and mitigating disease progression. Moreover, by promoting the clearance of senescent cells or modulating their secretory profiles, MSCs could potentially reverse some age-related declines in kidney function.This review article intends to shed light on the present discoveries concerning the role of cellular senescence in kidney aging and diseases. Furthermore, it outlines the role of senotherapeutics utilized to alleviate kidney damage and aging. It also highlights the possible impact of MSCs secretome on mitigating kidney injury and prolonging lifespan across various models of kidney diseases as a novel senotherapy.
Competing Interests: Declarations. Ethics approval and consent to participate: This study was approved by Tabriz University of Medical Sciences, Tabriz, Iran (Ethical code: IR.TBZMED.REC.1402.472). Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje